Regencell Bioscience Holdings Ltd (RGC)
Regencell Bioscience Holdings Ltd is a Hong Kong-based healthcare company focused on Traditional Chinese medicine (TCM) bioscience. The company is engaged in research, development, and commercialization efforts aimed at therapies for neurocognitive disorders and degeneration, with an emphasis on attention deficit hyperactivity disorder and autism spectrum disorder. Incorporated in 2014, Regencell Bioscience is headquartered in Causeway Bay, Hong Kong. Its common stock trades on the NASDAQ under the symbol RGC.
Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Market Outlook FAQ
Jump directly to the stock analysis sections supported by the latest available data.
Data update note:
Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Overall Financial Health | Dividend Yield | Next Earnings Date | Price-to-Book Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-RGC
|
$2.87
|
-53.9% Downside
|
Expensive
|
Not available
|
Not available
|
Fair
|
0.0%
|
October 28, 2026
|
2,405.5x
|
3.087 B
|
2.931 B
|
0.0%
|
11.4%
|
-43.5
|
58.9%
|
